Maria Elisa Mancuso on NXT007 Prophylaxis in People With Haemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Maria Elisa Mancuso presented new ASH data on NXT007 prophylaxis in people with haemophilia A (PwHA), with and without FVIII inhibitors – a global, open-label Phase I/II multiple‑ascending dose (MAD) study (first 3 cohorts).
NXT007, a next‑generation FVIII‑mimetic bispecific antibody derived from emicizumab, showed a very consistent picture across pharmacokinetics (PK), pharmacodynamics (PD) and clinical outcomes
- Safety/tolerability:
Well tolerated across all dose cohorts, with no thromboembolic events (TEs) / thrombotic microangiopathies (TMAs), no discontinuations due to adverse events (AEs) and D‑dimer levels remaining in the normal range.
- Pharmacokinetics:
Dose‑proportional PK with sustained plasma concentrations within the predicted therapeutic range.
- Thrombin generation (TG):
Mean TG peak heights in Cohorts 2 and 3 at steady state were comparable to normal‑range FVIII levels.
- Bleeding outcomes:
Annualized bleeding rates (ABRs) for treated bleeds markedly decreased after starting NXT007; the majority of participants (≈86%) had zero treated bleeds during the maintenance period. One striking outlier with multiple bleeds had an abnormal vessel in a replaced knee, nicely reminding us that not every bleed signal is “drug failure”.
- Immunogenicity:
Most participants developed treatment‑induced anti‑drug antibodies (ADAs) around Day 29, yet these ADAs had no detectable impact on NXT007 PK, efficacy or safety, and showed no cross‑reactivity with emicizumab.
These Phase I/II results strongly support progression of NXT007 into Phase III trials
Guy Young asked an excellent question: If high ADA rates do not translate into altered PK, reduced efficacy or safety concerns, what is the true clinical relevance of routine ADA testing for these bispecifics?”
Find more posts from ASH2025 on Hemostasis Today.
-
Dec 11, 2025, 06:23Robert Negrin is the President of ASH for 2026
-
Dec 11, 2025, 03:36Susan Galbraith on AstraZeneca’s Grand Presence at ASH25
-
Dec 10, 2025, 23:50Abdul Mannan: Two Battles, One Patient – Why Women on Anticoagulants Need Better Coordinated Care
-
Dec 10, 2025, 22:0212 Posts Not to Miss From the ASH 2025 – Wolfgang Miesbach
-
Dec 10, 2025, 17:22In the Fight for Hematology: Adetokunbo O’s Reflections from ASH25
-
Dec 10, 2025, 17:11Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
-
Dec 10, 2025, 16:37Arthur Allen – The New President-Elect of the Anticoagulation Forum Board of Directors
-
Dec 10, 2025, 16:29Matthew D Neal: An Oasis in the Platelet Desert?
-
Dec 10, 2025, 16:14Yashpal Singh Rawat: Fortis Memorial Research Institute Made Its Positive Mark at ASH